Original Research Article
Obesity, Abdominal Obesity and Alzheimer DiseaseRazay G.a · Vreugdenhil A.a · Wilcock G.b
aLaunceston General Hospital, University of Tasmania, Launceston, Australia; bFrenchay Hospital, University of Bristol, Bristol, UK
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Background/Aims: Obesity has a strong association with vascular and metabolic diseases, which have been linked with Alzheimer disease (AD). While recent studies have reported an association between mid-life obesity and dementia, the role of later-life obesity is less clear. This study investigated the relation between AD, obesity and abdominal obesity at later-life in a case-control study. Methods: Participants were 50 consecutive patients with probable AD from memory disorders clinics in Launceston, Australia, and Bristol, England, and 75 cognitively normal controls. Height and weight [from which body mass index (BMI) was calculated] and hip and waist circumferences (from which waist-hip ratio was calculated) were measured. Participants were classified according to their BMI as: underweight (BMI <20.0 kg/m2); normal weight (BMI 20.0–24.9 kg/m2); overweight (BMI 25–29.9 kg/m2), or obese (BMI ≧30 kg/m2). They were classified as abdominally obese if their waist-hip ratio was >0.9 (men) or >0.8 (women). Results: AD was associated with obesity [OR 9.5, 95% CI 2.4–37.3, p = 0.001], underweight (OR 5.4, CI 0.9–33.7, p = 0.07) and abdominal obesity (OR 2.5, CI 1.1–5.7, p = 0.027) using logistic regression analyses adjusted for age, sex and location. The inclusion of metabolic risk factors in the model increased the ORs for obesity (OR 12.6, CI 2.8–56.5, p = 0.001) and underweight (OR 7.9, CI 1.0–66.3, p = 0.056). Conclusion: AD may be associated with obesity, underweight and abdominal obesity at later life. Larger prospective studies are required to investigate this further.
© 2006 S. Karger AG, Basel
- Flegal KM, Carroll MD, Ogden CL, Johnson CL: Prevalence and trends in obesity among US adults, 1999–2000. JAMA 2002;288:1723–1727.
- Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, et al: Midlife vascular risk factors and Alzheimer’s disease in later life: longitudinal, population based study. BMJ 2001;322:1447–1451.
- Whitmer RA, Gunderson EP, Barrett-Connor E, Quesenberry CP, Yaffe K: Obesity in middle age and future risk of dementia: a 27-year longitudinal population-based study. BMJ 2005;330:1360.
- Kivipelto M, Ngandu T, Fratiglioni L, Viitanen M, Kareholt I, Winblad B, et al: Obesity and vascular risk factors at mid-life and the risk of dementia and Alzheimer’s disease. Arch Neurol 2005;62:1556–1560.
- Gustafson D, Rothenberg E, Blennow K, Steen B, Skoog I: An 18-year follow-up of overweight and risk of Alzheimer’s disease. Arch Intern Med 2003;163:1524–1528.
- Razay G, Vreugdenhil A: Obesity in middle age and future risk of dementia: midlife obesity increases risk of future dementia. BMJ 2005;331:455.
- White H, Pieper C, Schmader K: The association of weight change in Alzheimer’s disease with severity of disease and mortality: a longitudinal analysis. J Am Geriatr Soc 1998;46:1223–1227.
- Barrett-Connor E, Edelstein SL, Corey-Bloom J, Weiderholt WC: Weight loss precedes dementia in community-dwelling older adults. J Am Geriatr Soc 1996;44:1147–1152.
- Jagust W, Harvey D, Mungas D, Haan M: Central obesity and the aging brain. Arch Neurol 2005;62:1545–1548.
Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, American Psychiatric Association, 1994, pp 138–142.
- McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-Alzheimer’s disease RDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34:939–944.
- Folstein MF, Folstein SE, McHugh PR: ‘Mini-mental state’. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–198.
- Dobiasova M, Frohlich JN: The plasma parameter log as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma. Clin Biochem 2001;34:583–588.
- Cameron AJ, Welborn TA, Zimmet PZ, Dunstan DW, Owen N, Salmon J, et al: Overweight and obesity in Australia: the 1999–2000 Australian diabetes, obesity and lifestyle study (AusDiab). Med J Aust 2003;178:427–432.
- Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P, et al: Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet 2005;366:1640–1649.
- Yaffe K, Kanaya A, Lindquist K, Simonsick EM, Harris T, Shorr RI, et al: The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA 2004;292:2237–2242.
- Alexander CM, Landsman PB, Teutsch SM, Haffner SM: NCEP-defined metabolic syndrome, diabetes and prevalence of coronary heart disease among NHANES III participants aged 50 years and older. Diabetes 2003;52:1210–1214.
- Hanson RL, Imperatore G, Bennett PH, Knowler WC: Components of the ‘metabolic syndrome’ and incidence of type 2 diabetes. Diabetes 2002;51:3120–3127.
- Watson GS, Craft S: The role of insulin resistance in the pathogenesis of Alzheimer’s disease: implications for treatment. CNS Drugs 2003;17:27–45.
- Hofman A, Ott A, Breteler MM, Bots ML, Slooter AJ, van Harskamp F, et al: Atherosclerosis, apolipoprotein E and prevalence of dementia and Alzheimer’s disease in the Rotterdam study. Lancet 1997;349:151–154.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.